Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory...
15 KB (1,511 words) - 05:31, 2 July 2024
into a licensing agreement with Merck & Co. Inc. to acquire rights for Tildrakizumab (MK- 3222) for treatment of chronic plaque psoriasis, in order to further...
17 KB (1,554 words) - 07:22, 13 October 2024
Ixekizumab L04AC14 Sarilumab L04AC15 Sirukumab L04AC16 Guselkumab L04AC17 Tildrakizumab L04AC18 Risankizumab L04AC19 Satralizumab L04AC20 Netakimab L04AC21...
3 KB (367 words) - 15:37, 25 January 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
23 KB (1,813 words) - 18:30, 5 November 2024
Ritlecitinib Rozanolixizumab Sarilumab Satralizumab Siltuximab Siponimod Sirukumab Spesolimab Sutimlimab Telitacicept Tildrakizumab Tofacitinib Upadacitinib...
7 KB (299 words) - 13:45, 27 April 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
38 KB (3,075 words) - 05:52, 21 October 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
17 KB (1,245 words) - 14:04, 2 September 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
15 KB (1,089 words) - 18:39, 16 October 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
22 KB (2,581 words) - 20:03, 21 June 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
43 KB (3,675 words) - 23:48, 14 October 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
63 KB (7,473 words) - 05:58, 16 October 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
24 KB (2,084 words) - 05:31, 21 October 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
18 KB (1,656 words) - 19:23, 6 November 2024
reported to have faster onset of action in treatment of psoriasis than tildrakizumab or risankizumab, which are inhibitors of the p19 subunit of IL-23. However...
20 KB (2,186 words) - 01:58, 3 November 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
12 KB (1,323 words) - 14:55, 7 September 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
26 KB (3,273 words) - 08:48, 14 October 2024
Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab†Lebrikizumab Olokizumab†Perakizumab Risankizumab Spesolimab Tildrakizumab Veterinary Lokivetmab...
38 KB (4,316 words) - 10:24, 26 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
14 KB (1,578 words) - 23:52, 11 October 2024
Spasticity in Multiple Sclerosis Monovo Mometasone Psoriasis Ilumetri Tildrakizumab Psoriasis Ebglyss Lebrikizumab Atopic Dermatitis Wynzora Calcipotriol/Betamethasone...
15 KB (1,054 words) - 21:35, 10 September 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
45 KB (4,194 words) - 12:36, 2 May 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
14 KB (1,147 words) - 07:33, 11 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
19 KB (2,293 words) - 11:05, 8 March 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
5 KB (286 words) - 05:02, 7 September 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
50 KB (6,093 words) - 20:45, 19 November 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
12 KB (1,289 words) - 19:20, 4 December 2023
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
43 KB (5,000 words) - 12:13, 15 September 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
9 KB (587 words) - 12:00, 30 September 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
24 KB (2,881 words) - 19:11, 20 November 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
40 KB (4,619 words) - 06:54, 7 November 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
16 KB (1,451 words) - 18:24, 2 August 2024